Trial reportEuropean heart journal. Acute cardiovascular care2026
The impact of blood pressure targets on haemodynamics in patients with cardiogenic shock caused by infarction-related out-of-hospital cardiac arrest: a substudy of the BOX-trial.
Trial report in European heart journal. Acute cardiovascular care, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
aimsNoradrenaline is frequently used to increase mean arterial pressure (MAP) in patients with cardiogenic shock caused by infarction-related out-of-hospital cardiac arrest (OHCA-AMICS). This Blood pressure and Oxygenation-Targets after OHCA (BOX)-trial subanalysis investigates the impact of different noradrenaline-mediated MAP-targets on overall haemodynamics and outcomes in OHCA-AMICS patients. METHODS AND
resultsThe BOX-trial compared randomized, double-blinded MAP-targets of 63 mmHg (low-target) and 77 mmHg (high-target) in comatose OHCA patients. For this subanalysis, patients meeting eligibility criteria for AMICS according to the ongoing NORshock trial were included (percutaneous coronary intervention, hypotension, signs of hypoperfusion, and <30 min to return of spontaneous circulation). Haemodynamic parameters assessed were cardiac index (CI) and pulmonary capillary wedge pressure (PCWP). Markers of tissue perfusion comprised mixed venous oxygen saturation (SvO2) and lactate. Clinical endpoints included 365-day mortality, renal replacement therapy (RRT), and neurological outcomes. Within the cohort of 258 patients (low-target n = 132, high-target n = 126), mean age was 63 (±11) years, 84% were male, and patient characteristics were well balanced between groups. The high-target group received significantly higher doses of noradrenaline. CI increased over time in both groups (low-target: 1.50→2.88; high-target: 1.77→2.92 L/min/m2). Despite 8-19% higher CIs during the first 24 h, the high-target group consistently exhibited higher PCWPs. SvO2 was higher in the high-target group. Lactate levels were comparable and, on average, normalized in both groups within 6 h. Mortality, need for RRT, and neurological outcomes did not differ significantly.
conclusionIn OHCA-AMICS patients, higher noradrenaline-mediated MAP increased CI and SvO2 but did not enhance tissue perfusion or clinical outcomes, and were associated with higher left-sided filling pressures.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.